Pliant Therapeutics: Phase 2a trial of bexotegrast shows reduced lung collagen and improved lung function in IPF

PLIANT THERAPEUTICS, INC.

Bexotegrast 160 mg reduced total lung collagen on PET imaging vs. increased collagen on placebo over 12 weeks.
Treated patients showed improvements in forced vital capacity (FVC) and cough severity at all timepoints vs. placebo.
No drug-related serious adverse events or discontinuations reported; most TEAEs mild.
Trial enrolled 10 patients (7 active, 3 placebo); 8 on standard of care (mostly nintedanib).
Biomarkers integrin beta-6 and PRO-C3 reduced in bexotegrast arm vs. placebo at weeks 4 and 12.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.